Cardiol Therapeutics (TSE:CRDL) Shares Down 14.6% – Here’s What Happened

Cardiol Therapeutics Inc. (TSE:CRDL) traded down 14.6% on Tuesday . The stock traded as low as C$1.24 and last traded at C$1.29. 551,069 shares were traded during mid-day trading, an increase of 405% from the average session volume of 109,045 shares. The stock had previously closed at C$1.51.

Cardiol Therapeutics Price Performance

The company has a debt-to-equity ratio of 1.59, a current ratio of 2.49 and a quick ratio of 6.84. The stock has a market capitalization of C$133.00 million, a price-to-earnings ratio of -3.24 and a beta of 1.31. The company has a 50-day simple moving average of C$1.49 and a two-hundred day simple moving average of C$1.64.

Cardiol Therapeutics (TSE:CRDL) last released its quarterly earnings results on Thursday, November 13th. The company reported C($0.12) EPS for the quarter. On average, equities research analysts predict that Cardiol Therapeutics Inc. will post -0.49 earnings per share for the current year.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.